LEXINGTON, Mass., July 25,
2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib
(CA-4948), an orally available, small molecule IRAK4 inhibitor,
today announced that the Company will report its second quarter
2024 financial and operating results on Thursday, August 1, 2024, at 8:00 a.m. ET. Management will host a conference
call and simultaneous webcast on the same day at 8:30 a.m. ET.
Participants may join by dialing (800)-836-8184 from the
United States or (646)-357-8785 from other locations or a
live audio webcast can be accessed here from the investor
section of the Curis website. A replay of the conference call will
be available at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study in patients with relapsed/refractory primary
central nervous system lymphoma (PCNSL) in combination with the BTK
inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim
Leukemia study in patients with relapsed/refractory acute myeloid
leukemia (AML) and relapsed/refractory high risk myelodysplastic
syndrome (hrMDS) with either a FLT3 mutation or a splicing factor
mutation (U2AF1 or SF3B2), and as a frontline combination therapy
with azacitidine and venetoclax in patents with AML. Emavusertib
has received Orphan Drug Designation from the U.S. Food and Drug
Administration for the treatment of AML and MDS. Curis, through its
2015 collaboration with Aurigene, has the exclusive license to
emavusertib (CA-4948). Curis licensed its rights to Erivedge® to
Genentech, a member of the Roche Group, under which they are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website at
www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-report-second-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-1-2024-302206055.html
SOURCE Curis, Inc.